Skip to main content

Branded

  • AbbVie grows oncology pipeline with Stemcentrx acquisition

    NORTH CHICAGO — Biopharmaceutical company AbbVie on Thursday announced its planned acquisition of Stemcentrx and its late-stage potential treatment for small cell lung cancer, Rova-T (rovalpituzumab tesirine). 
     

  • FDA approves Exelixis’ Cabometyx

    SILVER SPRING, Md. — The Food and Drug Administration has approved Exelixis’ Cabometyx (cabozantinib) tablets, the company announced this week. Cabometyx is indicated to treat patients with advanced renal cell carcinoma who have previously received anti-angiogenic treatment. 
     

  • Researchers find four supplements that boost efficacy of antidepressants

    PARKVILLE, Australia - An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression.
     
    Omega 3 fish oils, S-adenosylmethionine (SAMe), methylfolate (bioactive form of folate) and vitamin D, were all found to boost the effects of medication.
     

  • FDA approves new use for AbbVie’s Viekira Pak

    SILVER SPRING, Md. — The Food and Drug administration have approved AbbVie’s Viekira Pak for use without ribavirin to treat certain patients with hepatitis C.
     
    The new indication for Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) will allow it to be used for patients with genotype 1b chronic hepatitis C and compensated cirrhosis. 
     

  • Upsher-Smith announces Androxy re-availability

    MAPLE GROVE, Minn. — Upsher-Smith Laboratories on Monday announced that its Androxy (fluoxymesterone) tablets were once again available exclusively through the company. The drug is a synthetic androgen available in 100-count bottles of 10-mg tablets. 
     
    “As the only supplier of fluoxymesterone tablets in the United States, we have made it a priority to get this medication back on the market,” Upsher-Smith president Rusty Field said. “We are pleased that physicians and patients can once again access Androxy.”

  • Allergan acquires Topokine Therapeutics

    DUBLIN and BOSTON — Allergan on Thursday announced that it had acquired topical dermatology company Topokine Therapeutics, which develops medicine for fat reduction.
     
    The acquisition saw Allergan pauying $85 million up front alongside success-based development and milestones for Topokine’s XAF5, an under-eye bag treatment. 
     

  • Dr. Reddy’s subsidiary announces Zembrace SymTouch U.S. availability

    HYDERABAD, India. — Dr. Reddy’s Laboratories subsidiary Promius Pharma announced Tuesday that its Zembrace SymTouch (sumatriptan injection) is now commercially available in the United Stated. 
     
    The pre-filled, low-dose autoinjector contains 3 mg of sumatriptan, which can lead to rapid migraine relief. 
     

  • Tris Pharma launches Dyanavel XR

    MONMOUTH JUNCTION, N.J. — Tris Pharma announced this week that it had launched its Dyanavel XR (amphetamine) extended-release liquid for oral suspension. The drug is indicated to treat attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and older
     
X
This ad will auto-close in 10 seconds